Related Experiment Videos

Molecular cloning of the human CAK1 gene encoding a cyclin-dependent kinase-activating kinase

L Wu1, A Yee, L Liu

  • 1Division of Orthopaedic Surgery, Research Institute of Childrens Hospital Los Angeles, California.

Oncogene
|July 1, 1994
PubMed

Insights

Researchers cloned the human homologue of Xenopus Cdk-activating kinase (Cak), named (HS)CAK1. This kinase is crucial for activating Cdc2, a key cell cycle regulator, and may be a therapeutic target for proliferative disorders.

Area of Science:

  • Molecular Biology
  • Cell Cycle Regulation
  • Oncology

Background:

  • Cyclin-dependent kinases (CDKs) regulate cell cycle transitions.
  • Abnormal CDK activity and regulation are implicated in cancer.
  • Cdc2 activation requires phosphorylation at Thr-161, mediated by a Cdk-activating kinase (CAK).

Purpose of the Study:

  • To molecularly clone and characterize the human homologue of Xenopus Cdk-activating kinase (CAK).
  • To investigate the role of human CAK (HSCAK1) in Cdc2 activation.
  • To explore the potential of HSCAK1 as a therapeutic target for proliferative disorders.

Main Methods:

  • Molecular cloning of the human CAK gene, designated (HS)CAK1.
  • Sequence analysis and comparison with Xenopus MO15.
  • Immunological studies using anti-Cak antibodies to detect human Cdc2-activating kinase activity.

Main Results:

  • The human CAK homologue, (HS)CAK1, was successfully cloned.
  • (HS)CAK1 shares significant amino acid homology (approximately 87%) with Xenopus MO15, particularly in the catalytic domain.
  • Immunological studies confirmed the presence of specific Cdc2-activating kinase activity in human preparations.

Conclusions:

  • The molecular characterization of (HS)CAK1 provides a basis for studying its physiological regulation.
  • HSCAK1 is the human homologue of the Cdk-activating kinase essential for Cdc2 activation.
  • HSCAK1 represents a potential therapeutic target for treating proliferative disorders like cancer.

Related Concept Videos